P Mark Hogarth

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2567352/publications.pdf

Version: 2024-02-01

211 papers 8,117 citations

50566 48 h-index 78623 77 g-index

222 all docs 222 docs citations

times ranked

222

8796 citing authors

#	Article	IF	CITATIONS
1	Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. Journal of Hepatology, 2022, 76, 34-45.	1.8	12
2	Adults with Plasmodium falciparum malaria have higher magnitude and quality of circulating T-follicular helper cells compared to children. EBioMedicine, 2022, 75, 103784.	2.7	6
3	A Quantitative Approach to Unravel the Role of Host Genetics in IgG-Fcl³R Complex Formation After Vaccination. Frontiers in Immunology, 2022, 13, 820148.	2.2	1
4	Age-dependent changes in circulating Tfh cells influence development of functional malaria antibodies in children. Nature Communications, 2022, 13, .	5.8	6
5	Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial. Journal of Infectious Diseases, 2021, 224, 1128-1138.	1.9	38
6	Mechanisms and targets of $Fc\hat{l}^3$ -receptor mediated immunity to malaria sporozoites. Nature Communications, 2021, 12, 1742.	5.8	38
7	Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice. Frontiers in Immunology, 2021, 12, 641421.	2.2	9
8	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nature Communications, 2021, 12, 2037.	5.8	125
9	PLASMA ACE2 ACTIVITY IS INCREASED IN PATIENTS RECOVERED FROM SARS-COV-2 INFECTION: IMPLICATIONS FOR THE PROLONGED CONSEQUENCES OF COVID-19. Journal of Hypertension, 2021, 39, e394.	0.3	3
10	Improved HIV-positive infant survival is correlated with high levels of HIV-specific ADCC activity in multiple cohorts. Cell Reports Medicine, 2021, 2, 100254.	3.3	16
11	CytoBas: Precision componentâ€resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3028-3040.	2.7	8
12	Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Cell Reports Medicine, 2021, 2, 100296.	3.3	56
13	Developing a multivariate prediction model of antibody features associated with protection of malaria-infected pregnant women from placental malaria. ELife, 2021, 10, .	2.8	18
14	Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies. Journal of Virology, 2021, 95, e0021921.	1.5	7
15	Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. Journal of Virology, 2021, 95, e0079621.	1.5	6
16	A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination. Cell Reports Medicine, 2021, 2, 100386.	3.3	8
17	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 1383-1394.	4.6	82
18	Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. European Respiratory Journal, 2021, 57, 2003730.	3.1	100

#	Article	IF	CITATIONS
19	Fc Binding by Fcl³Rlla Is Essential for Cellular Activation by the Anti-Fcl³Rlla mAbs 8.26 and 8.2. Frontiers in Immunology, 2021, 12, 666813.	2.2	2
20	Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	4
21	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 2021, 74, 103729.	2.7	29
22	Plasma levels of the soluble form of the Fcl^3RIIa receptor vary with receptor polymorphisms and are elevated in rheumatoid arthritis. Platelets, 2020, 31, 392-398.	1.1	1
23	Distinguishing human peripheral blood CD16 + myeloid cells based on phenotypic characteristics. Journal of Leukocyte Biology, 2020, 107, 323-339.	1.5	8
24	Influenzaâ€specific IgG1 ⁺ memory Bâ€eell numbers increase upon booster vaccination in healthy adults but not in patients with predominantly antibody deficiency. Clinical and Translational Immunology, 2020, 9, e1199.	1.7	12
25	Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Science Immunology, 2020, 5, .	5.6	244
26	Innate and Adaptive Anti-SIV Responses in Macaque Semen: Implications for Infectivity and Risk of Transmission. Frontiers in Immunology, 2020, 11, 850.	2.2	7
27	Harnessing the immune system <i>via</i> Fcî³R function in immune therapy: a pathway to nextâ€gen mAbs. Immunology and Cell Biology, 2020, 98, 287-304.	1.0	47
28	Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults. Vaccine, 2020, 38, 2368-2377.	1.7	10
29	Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection. Cell Reports Medicine, 2020, 1, 100157.	3.3	26
30	CD300f epitopes are specific targets for acute myeloid leukemia with monocytic differentiation. Molecular Oncology, 2019, 13, 2107-2120.	2.1	9
31	Boosting of Markers of $Fc\hat{l}^3$ Receptor Function in Anti-HIV Antibodies During Structured Treatment Interruption. AIDS Research and Human Retroviruses, 2019, 35, 842-852.	0.5	1
32	The Human FcÎ ³ RII (CD32) Family of Leukocyte FcR in Health and Disease. Frontiers in Immunology, 2019, 10, 464.	2.2	111
33	Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Theranostics, 2019, 9, 1154-1169.	4.6	32
34	Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind $Fc\hat{l}^3$ Receptors: Implications for Measuring Fc Dependent Antibody Functions. Frontiers in Immunology, 2019, 10, 2415.	2.2	35
35	Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells. Journal of Virology, 2019, 93, .	1.5	44
36	The cell surface phenotype of human dendritic cells. Seminars in Cell and Developmental Biology, 2019, 86, 3-14.	2.3	45

#	Article	IF	Citations
37	CD83 is a leading therapeutic target in Hodgkin and mantle cell lymphoma. Pathology, 2018, 50, S101.	0.3	О
38	Antibody-Dependent Cellular Cytotoxicity Responses to Seasonal Influenza Vaccination in Older Adults. Journal of Infectious Diseases, 2018, 217, 12-23.	1.9	37
39	Dimeric $Fc\hat{l}^3R$ ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thromobocytopenia. Journal of Thrombosis and Haemostasis, 2018, 16, 2520-2525.	1.9	4
40	The Rare Anaphylaxis-Associated $Fc\hat{l}^3RIIa3$ Exhibits Distinct Characteristics From the Canonical $Fc\hat{l}^3RIIa1$. Frontiers in Immunology, 2018, 9, 1809.	2.2	7
41	Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection. Journal of Infectious Diseases, 2018, 218, 1383-1393.	1.9	8
42	Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. Journal of Clinical Investigation, 2018, 129, 182-191.	3.9	69
43	Dimeric FcÎ ³ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of FcÎ ³ Receptor Antibodies Induced by the RV144 Vaccine Trial. Journal of Immunology, 2017, 199, 816-826.	0.4	43
44	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. Journal of Virology, 2017, 91, .	1.5	14
45	Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults. Vaccine, 2017, 35, 6451-6458.	1.7	16
46	HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV. Journal of Virology, 2017, 91, .	1.5	59
47	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Science Translational Medicine, 2017, 9, .	5.8	45
48	Distinctive expression of interleukinâ€23 receptor subunits on human Th17 and γδT cells. Immunology and Cell Biology, 2017, 95, 272-279.	1.0	13
49	Targeting Activated Platelets: A Unique and Potentially Universal Approach for Cancer Imaging. Theranostics, 2017, 7, 2565-2574.	4.6	43
50	A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Frontiers in Immunology, 2017, 8, 595.	2.2	20
51	Fc functional antibodies in humans with severe H7N9 and seasonal influenza. JCI Insight, 2017, 2, .	2.3	39
52	Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field. Current HIV Research, 2017, 15, 202-215.	0.2	28
53	Dimeric $Fc\hat{l}^3R$ Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG. Journal of Immunology, 2016, 197, 1507-1516.	0.4	90
54	Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine. Journal of Virology, 2016, 90, 5724-5734.	1.5	52

#	Article	lF	Citations
55	Targeting B cells in treatment of autoimmunity. Current Opinion in Immunology, 2016, 43, 39-45.	2.4	52
56	Clarifying the Confusion between Cytokine and Fc Receptor "Common Gamma Chain― Immunity, 2016, 45, 225-226.	6.6	37
57	Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Brain and Behavior, 2016, 6, e00516.	1.0	6
58	What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine, 2016, 8, 277-290.	2.7	67
59	The highâ€affinity receptor for IgG, FcγRl, of humans and nonâ€human primates. Immunological Reviews, 2015, 268, 175-191.	2.8	15
60	Fc Receptors: Introduction. Immunological Reviews, 2015, 268, 1-5.	2.8	12
61	CD14hiCD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so. BMC Medicine, 2015, 13, 154.	2.3	43
62	TLR3 drives IRF6â€dependent ILâ€23p19 expression and p19/EBI3 heterodimer formation in keratinocytes. Immunology and Cell Biology, 2015, 93, 771-779.	1.0	49
63	The Fcl ³ R of Humans and Non-human Primates and Their Interaction with IgG: Implications for Induction of Inflammation, Resistance to Infection and the Use of Therapeutic Monoclonal Antibodies. Current Topics in Microbiology and Immunology, 2014, 382, 321-352.	0.7	24
64	Polymorphisms and Interspecies Differences of the Activating and Inhibitory $Fc\hat{l}^3RII$ of <i>Macaca nemestrina</i> Influence the Binding of Human IgG Subclasses. Journal of Immunology, 2014, 192, 792-803.	0.4	41
65	ZSWIM1: A novel biomarker in T helper cell differentiation. Immunology Letters, 2014, 160, 133-138.	1.1	11
66	Fcl $\hat{\mu}$ Receptor Expression in Human Airway Smooth Muscle Cells. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 560-560.	1.4	1
67	Isolation, expansion and characterisation of alloreactive human Th17 and Th1 cells. Immunology Letters, 2012, 143, 116-121.	1.1	1
68	Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nature Reviews Drug Discovery, 2012, 11, 311-331.	21.5	298
69	Functional Expression of IgG-Fc Receptors in Human Airway Smooth Muscle Cells. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 665-672.	1.4	27
70	Structural Basis for $Fc\hat{l}^3$ Rlla Recognition of Human IgG and Formation of Inflammatory Signaling Complexes. Journal of Immunology, 2011, 187, 3208-3217.	0.4	138
71	Interaction of Human, Rat, and Mouse Immunoglobulin A (IgA) with Staphylococcal Superantigen-like 7 (SSL7) Decoy Protein and Leukocyte IgA Receptor. Journal of Biological Chemistry, 2011, 286, 33118-33124.	1.6	16
72	lgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcγRIIA and FcγRIIB. Immunology Letters, 2010, 130, 57-65.	1,1	76

#	Article	IF	Citations
73	Transgenic mice expressing human $Fc\hat{l}^3R$ lla have enhanced sensitivity to induced autoimmune arthritis as well as elevated Th17 cells. Immunology Letters, 2010, 130, 82-88.	1.1	22
74	Inhibition of destructive autoimmune arthritis in $Fc\hat{l}^3R$ lla transgenic mice by small chemical entities. Immunology and Cell Biology, 2009, 87, 3-12.	1.0	36
75	FcÎ ³ RII restriction fragment length polymorphism (RFLP): analysis in systemic lupus erythematosus and scleroderma and evidence of an alpha gene duplication. Clinical and Experimental Immunology, 2008, 83, 47-51.	1.1	6
76	Recombinant soluble $Fc\hat{l}^3RII$ inhibits immune complex precipitation. Clinical and Experimental Immunology, 2008, 102, 620-625.	1.1	19
77	An FcÎ ³ Rlla-binding peptide that mimics the interaction between FcÎ ³ Rlla and IgG. Molecular Immunology, 2008, 45, 307-319.	1.0	11
78	Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing Fc \hat{I}^3 Rlla. Blood, 2008, 111, 165-174.	0.6	77
79	Fc Receptors. Advances in Experimental Medicine and Biology, 2008, 640, 22-34.	0.8	24
80	Structural basis for evasion of IgA immunity by <i>Staphylococcus aureus</i> revealed in the complex of SSL7 with Fc of human IgA1. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15051-15056.	3.3	105
81	Impaired "outside-in―integrin αIIbβ3 signaling and thrombus stability in TSSC6-deficient mice. Blood, 2006, 108, 1911-1918.	0.6	86
82	IgA receptors in health and disease. Tissue Antigens, 2006, 68, 103-114.	1.0	96
83	Raft localisation of $Fc\hat{l}^3$ Rlla and efficient signaling are dependent on palmitoylation of cysteine 208. Immunology Letters, 2006, 104, 118-123.	1.1	32
84	FcÎ ³ RII and multi-system autoimmune disease. Seminars in Immunopathology, 2006, 28, 329-338.	4.0	10
85	A Common Site of the Fc Receptor \hat{I}^3 Subunit Interacts with the Unrelated Immunoreceptors Fc $\hat{I}\pm RI$ and Fc $\hat{I}\mu RI$. Journal of Biological Chemistry, 2006, 281, 17108-17113.	1.6	22
86	Alteration of the $Fc\hat{l}^3$ Rlla Dimer Interface Affects Receptor Signaling but Not Ligand Binding. Journal of Immunology, 2006, 176, 7489-7494.	0.4	33
87	A Competitive Mechanism for Staphylococcal Toxin SSL7 Inhibiting the Leukocyte IgA Receptor, Fc \hat{l} ±RI, Is Revealed by SSL7 Binding at the C \hat{l} ±2/C \hat{l} ±3 Interface of IgA. Journal of Biological Chemistry, 2006, 281, 1389-1393.	1.6	43
88	Antigen delivery via two molecules on the CD8- dendritic cell subset induces humoral immunity in the absence of conventional "danger― European Journal of Immunology, 2005, 35, 2815-2825.	1.6	71
89	Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcl ³ receptor lla-transgenic mice. Arthritis and Rheumatism, 2005, 52, 3220-3229.	6.7	73
90	The Inhibitory Co-Receptor, PECAM-1 Provides a Protective Effect in Suppression of Collagen-Induced Arthritis. Journal of Clinical Immunology, 2005, 25, 19-28.	2.0	47

#	Article	IF	CITATIONS
91	Fc Receptor \hat{I}^3 Chain Residues at the Interface of the Cytoplasmic and Transmembrane Domains Affect Association with Fc \hat{I} ±RI, Surface Expression, and Function. Journal of Biological Chemistry, 2004, 279, 26339-26345.	1.6	20
92	C5a Initiates the Inflammatory Cascade in Immune Complex Peritonitis. Journal of Immunology, 2004, 173, 3437-3445.	0.4	130
93	Structural Convergence of Antibody Binding of Carbohydrate Determinants in Lewis Y Tumor Antigens. Journal of Molecular Biology, 2004, 340, 809-818.	2.0	53
94	The tetraspanin superfamily member CD151 regulates outside-in integrin $\hat{l}\pm llb\hat{l}^23$ signaling and platelet function. Blood, 2004, 104, 2368-2375.	0.6	110
95	Immunoglobulin (Fc) Receptors. , 2004, , 411-416.		0
96	The role of $Fc\hat{l}^3R$ IIa as an inflammatory mediator in rheumatoid arthritis and systemic lupus erythematosus. Immunology and Cell Biology, 2003, 81, 374-381.	1.0	41
97	Soluble FcgammaRIIa inhibits rheumatoid factor binding to immune complexes. Immunology, 2003, 109, 246-254.	2.0	30
98	Unique Monoclonal Antibodies Define Expression of FcγRl on Macrophages and Mast Cell Lines and Demonstrate Heterogeneity Among Subcutaneous and Other Dendritic Cells. Journal of Immunology, 2003, 170, 2549-2556.	0.4	46
99	Physical proximity and functional interplay of PECAM-1 with the Fc receptor FcÎ ³ RlIa on the platelet plasma membrane. Blood, 2003, 102, 3637-3645.	0.6	51
100	Mutagenesis Within Human Fcl $\hat{\mu}$ Ril± Differentially Affects Human and Murine IgE Binding. Journal of Immunology, 2002, 168, 1787-1795.	0.4	12
101	Fcl ³ RI-Deficient Mice Show Multiple Alterations to Inflammatory and Immune Responses. Immunity, 2002, 16, 379-389.	6.6	186
102	Fc receptors are major mediators of antibody based inflammation in autoimmunity. Current Opinion in Immunology, 2002, 14, 798-802.	2.4	177
103	Isolation, Tissue Distribution, and Chromosomal Localization of a Novel Testis-Specific Human Four-Transmembrane Gene Related to CD20 and Fc \parallel µRl- \hat{l}^2 . Biochemical and Biophysical Research Communications, 2001, 280, 374-379.	1.0	15
104	The Interaction of $Fclength{\hat{l}}\pm RI$ with IgA and Its Implications for Ligand Binding by Immunoreceptors of the Leukocyte Receptor Cluster. Journal of Immunology, 2001, 166, 1781-1789.	0.4	79
105	The Fc receptor family structure based strategies for the development of anti-inflammatory drugs. , 2001, , 107-114.		0
106	Monoclonal antibodies and synthetic peptides define the active site of FclµRl and a potential receptor antagonist. Allergy: European Journal of Allergy and Clinical Immunology, 2000, 55, 609-619.	2.7	20
107	Mouse Fc??RI: identification and functional characterization of five new alleles. Immunogenetics, 2000, 51, 206-211.	1.2	18
108	The IgG Fc Contains Distinct Fc Receptor (FcR) Binding Sites: The Leukocyte Receptors FcÎ ³ RI and FcÎ ³ RIIa Bind to a Region in the Fc Distinct from That Recognized by Neonatal FcR and Protein A. Journal of Immunology, 2000, 164, 5313-5318.	0.4	130

#	Article	IF	CITATIONS
109	Immunoglobulin G3 Antibodies Specific for the 19-Kilodalton Carboxyl-Terminal Fragment of Plasmodium yoelii Merozoite Surface Protein 1 Transfer Protection to Mice Deficient in Fc-Î ³ Rl Receptors. Infection and Immunity, 2000, 68, 3019-3022.	1.0	29
110	Domain One of the High Affinity IgE Receptor, Fcl μ RI, Regulates Binding to IgE through Its Interface with Domain Two. Journal of Biological Chemistry, 2000, 275, 9664-9672.	1.6	13
111	INHIBITION OF HYPERACUTE TRANSPLANT REJECTION BY SOLUBLE PROTEINS WITH THE FUNCTIONAL DOMAINS OF CD46 AND Fc??RII1. Transplantation, 2000, 69, 1128-1136.	0.5	12
112	Fine Structure Analysis of Interaction of Fcl μ RI with IgE. Journal of Biological Chemistry, 1999, 274, 13345-13352.	1.6	29
113	Biochemical analysis and crystallisation of Fc \hat{l}^3 RlIa, the low affinity receptor for IgG. Immunology Letters, 1999, 68, 17-23.	1.1	32
114	Crystal structure of the human leukocyte Fc receptor, Fc gammaRlla. Nature Structural Biology, 1999, 6, 437-442.	9.7	169
115	Differential dissociation kinetics explain the binding preference of insulin-like growth factor binding protein-6 for insulin-like growth factor-II over insulin-like growth factor-I. FEBS Letters, 1999, 450, 240-244.	1.3	17
116	Identification of residues in the first domain of human Fc alpha receptor essential for interaction with IgA. Journal of Immunology, 1999, 162, 2146-53.	0.4	81
117	Gain-of-function mutations in Fcl^3Rl of NOD mice: implications for the evolution of the Ig superfamily. EMBO Journal, 1998, 17, 3850-3857.	3.5	30
118	The second and third extracellular domains of Fc \hat{l}^3 RI (CD64) confer the unique high affinity binding of IgG2a. Molecular Immunology, 1998, 35, 989-996.	1.0	49
119	Molecular basis for the interaction of Fc receptors with immunoglobulins. , $1998,$, $11 ext{-}35.$		8
120	The role and use of recombinant receptors in the investigation and control of antibody-induced inflammation., 1998,, 215-231.		0
121	Identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adaptive immunity. Journal of Immunology, 1998, 160, 20-3.	0.4	87
122	The Structural Basis of the Interaction of IgE and FclµRI. Molecular Biology Intelligence Unit, 1997, , 7-32.	0.2	3
123	Immunoglobulin Fc receptors. Biomembranes: A Multi-Volume Treatise, 1996, , 269-314.	0.1	0
124	Extracellular Mutations of Non-obese Diabetic Mouse Fc ³ Rl Modify Surface Expression and Ligand Binding. Journal of Biological Chemistry, 1996, 271, 17091-17099.	1.6	13
125	Redirected Cytotoxic Effector Function. Journal of Biological Chemistry, 1996, 271, 21214-21220.	1.6	12
126	Multiple Regions of Human Fc \hat{i}^3 RII (CD32) Contribute to the Binding of IgG. Journal of Biological Chemistry, 1995, 270, 21188-21194.	1.6	64

#	Article	IF	CITATIONS
127	Expression of recombinant soluble Fc epsilon RI: function and tissue distribution studies. Immunology, 1995, 86, 392-8.	2.0	10
128	Characterization of FcR Ig-Binding Sites and Epitope Mapping. ImmunoMethods, 1994, 4, 17-24.	0.8	8
129	Molecular Basis of Fc Receptor Function. Advances in Immunology, 1994, 57, 1-127.	1.1	452
130	Identification of the IgG binding site of the human low affinity receptor for IgG Fc gamma RII. Enhancement and ablation of binding by site-directed mutagenesis. Journal of Biological Chemistry, 1994, 269, 15287-93.	1.6	55
131	Chimeric Fc receptors identify immunoglobulin-binding regions in human Fcl³RII and FclµRI. European Journal of Immunology, 1993, 23, 640-645.	1.6	57
132	The human FCG1 gene encoding the high-affinity Fc?RI maps to chromosome 1q21. Immunogenetics, 1993, 38, 307-9.	1.2	6
133	Linkage on chromosome 3 of autoimmune diabetes and defective Fc receptor for IgG in NOD mice. Science, 1993, 260, 695-698.	6.0	103
134	Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the Arthus reaction Journal of Experimental Medicine, 1993, 178, 1617-1628.	4.2	87
135	Identification of Functionally Active Regions of Fcl̂³ RII and Fc l̂μ RI. , 1993, , 451-456.		0
136	Biochemical characterization of murine Fc gamma Rl. Immunology, 1993, 78, 358-63.	2.0	17
137	Mapping epitopes of human Fc gamma RII (CDw32) with monoclonal antibodies and recombinant receptors. Journal of Immunology, 1993, 150, 1794-803.	0.4	56
138	Chromosomal mapping of the high affinity Fc? receptor gene. Immunogenetics, 1992, 35, 279-282.	1.2	29
139	Ly-15.2 and Ly-21.2 are distinct polymorphisms of the LFA-1 heavy chain. Immunogenetics, 1992, 36, 396-9.	1.2	2
140	Identification of the Immunoglobulin Binding Regions (IBR) of FcgammaRII and FceRI. Immunological Reviews, 1992, 125, 21-35.	2.8	42
141	Expression of the high responder/nonâ€responder human Fcl̂³RII. Analysis by PCR and transfection into FcR COS cells. Immunology and Cell Biology, 1992, 70, 79-87.	1.0	47
142	Effects of PMA, cytokines and dexamethasone on the expression of cell surface Fc receptors and mRNA in U937 cells. Immunology and Cell Biology, 1992, 70, 97-105.	1.0	19
143	FcÎ ³ receptors: Gene structure and receptor function. Immunologic Research, 1992, 11, 217-225.	1.3	18
144	Tumor-associated karyotypic lesions coselected with in vitro macrophage differentiation. Genes Chromosomes and Cancer, 1992, 5, 286-298.	1.5	5

#	Article	IF	CITATIONS
145	Functional recombinant soluble human Fc gamma RII. Transplantation Proceedings, 1992, 24, 2326-7.	0.3	3
146	Structure and mapping of the gene encoding mouse high affinity Fc gamma RI and chromosomal location of the human Fc gamma RI gene. Journal of Immunology, 1992, 148, 1570-5.	0.4	17
147	Soluble FcÎ ³ receptors II (FcÎ ³ RII) are generated by cleavage of membrane FcÎ ³ RII. European Journal of Immunology, 1991, 21, 231-234.	1.6	45
148	Structure of the mouse beta Fc gamma receptor II gene. Journal of Immunology, 1991, 146, 369-76.	0.4	34
149	Chimeric Fc receptors identify functional domains of the murine high affinity receptor for IgG. Journal of Immunology, 1991, 147, 1863-8.	0.4	53
150	Characterization and expression of an Fc gamma receptor cDNA cloned from rat natural killer cells Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 3425-3429.	3.3	15
151	Fc receptor gene translocation in a t(1;19) pre-B ALL cell line. Immunogenetics, 1990, 31, 356-360.	1.2	2
152	Mouse macrophage? subunit (CD11b) cDNA for the CR3 complement receptor/Mac-1 antigen. Immunogenetics, 1990, 31, 191-7.	1.2	15
153	Identification of the mouse? Fc?RII polymorphism by direct sequencing of amplified genomic DNA. Immunogenetics, 1990, 31, 202-6.	1.2	15
154	Molecular and functional studies of recombinant soluble $Fc\hat{l}^3$ receptors. Molecular Immunology, 1990, 27, 1201-1207.	1.0	15
155	Molecular cloning and expression of the mouse high affinity Fc receptor for IgG. Journal of Immunology, 1990, 144, 371-8.	0.4	58
156	Murine Type II Fc? Receptors and IgG-Binding Factors. Chemical Immunology and Allergy, 1989, 47, 21-78.	1.7	0
157	Murine Type II Fcl̂ Receptors and IgG-Binding Factors. Chemical Immunology and Allergy, 1989, 47, 21-40.	1.7	29
158	Murine Type II Fcl ³ Receptors and IgG-Binding Factors. Chemical Immunology and Allergy, 1989, 47, 41-60.	1.7	2
159	Murine Type II Fcl̂ Receptors and IgG-Binding Factors. Chemical Immunology and Allergy, 1989, 47, 61-78.	1.7	0
160	Modulation of human mononuclear phagocyte FcγRII mRNA and protein. Cellular Immunology, 1989, 124, 292-307.	1.4	23
161	CROSS-LINKING OF Ly 6-LINKED ALLOANTIGENS: ASSOCIATION BETWEEN ThB AND Ly 5. International Journal of Immunogenetics, 1989, 16, 33-43.	1.2	1
162	Recombinant soluble receptors for the $Fc\hat{l}^3$ portion inhibit antibody production in vitro. European Journal of Immunology, 1989, 19, 2263-2268.	1.6	48

#	Article	IF	CITATIONS
163	Molecular analysis of FcR of T cells and other cell types. Transplantation Proceedings, 1989, 21, 44-5.	0.3	2
164	THE EXPRESSION OF MURINE ALLOANTIGENS ON BLOOD LYMPHOCYTES. International Journal of Immunogenetics, 1988, 15, 281-293.	1.2	0
165	The 33 000 protein precipitated by Ly-6A.2-specific antibodies is not associated with the Ly-6 polymorphism. Immunogenetics, 1988, 28, 399-405.	1.2	2
166	Assignment of the gene coding for human FcRII (CD32) to bands g23g24 on chromosome 1. Immunogenetics, 1988, 28, 380-381.	1.2	35
167	The mouse Ly-12.1 specificity: genetic and biochemical relationship to Ly-1. Immunogenetics, 1988, 27, 383-387.	1.2	8
168	Evidence that Thyâ€1 and Lyâ€5 (Tâ€200) antigens interact with sulphated carbohydrates. Immunology and Cell Biology, 1988, 66, 221-230.	1.0	24
169	Molecular mechanisms regulating the expression of murine T-cell Fcγ receptor II. Molecular Immunology, 1988, 25, 1143-1150.	1.0	7
170	Molecular cloning of a human immunoglobulin G Fc receptor Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2240-2244.	3.3	119
171	The structure of the murine Fc receptor for IgG. Assignment of intrachain disulfide bonds, identification of N-linked glycosylation sites, and evidence for a fourth form of Fc receptor. Journal of Immunology, 1988, 140, 544-50.	0.4	13
172	The mouse Fc receptor for IgG (Ly-17): molecular cloning and specificity. Immunogenetics, 1987, 26, 161-168.	1.2	47
173	Mapping of the MouseLy-6, Xp-14, andGdc-1 loci to chromosome 15. Immunogenetics, 1987, 25, 21-27.	1.2	31
174	GENETIC AND BIOCHEMICAL CHARACTERIZATION OF ANTIGENS ENCODED BY THE LY-24 (Pgp-1) LOCUS1. International Journal of Immunogenetics, 1987, 14, 43-57.	1.2	6
175	The murine Fc receptor for immunoglobulin: purification, partial amino acid sequence, and isolation of cDNA clones Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 6980-6984.	3.3	74
176	Interrelationships of the ?Ly-6 complex? antigens. Immunogenetics, 1986, 23, 226-232.	1.2	23
177	Expression of Qa alloantigens on peripheral T cells: The relationship of the Qa-m2, 7, 8, 9 specificities. Immunogenetics, 1986, 24, 90-94.	1.2	2
178	Mapping of the murine Ly-15(LFA-1) locus to chromosome 7. Immunogenetics, 1986, 23, 348-349.	1.2	15
179	The Ly-15 alloantigenic system: a genetically determined polymorphism of the murine lymphocyte function-associated antigen-1 molecule Proceedings of the National Academy of Sciences of the United States of America, 1985, 82, 526-530.	3.3	24
180	Identification of two forms of the Ly-6.2 antigen showing differential expression. Immunogenetics, 1985, 21, 539-547.	1.2	17

#	Article	IF	CITATIONS
181	The mouse Ly-17 locus identifies a polymorphism of the Fc receptor. Immunogenetics, 1985, 22, 335-348.	1.2	49
182	Gm-3.2, A new granulocyte/macrophage alloantigen. Immunogenetics, 1985, 21, 61-70.	1.2	10
183	THE CELL SURFACE PHENOTYPE OF MOUSE NEUTROPHILS. International Journal of Immunogenetics, 1985, 12, 247-257.	1.2	2
184	Variable expression of Qa-m7, Qa-m8, and Qa-m9 antigenic determinants on primitive hemopoietic precursor cells. Journal of Cellular Physiology, 1985, 123, 451-458.	2.0	7
185	The distribution of the Qa-2 alloantigen on functional T lymphocytes. Journal of Immunology, 1985, 135, 1632-6.	0.4	8
186	An antigenic difference between cells forming early and late haematopoietic spleen colonies (CFU-S). Nature, 1984, 307, 638-641.	13.7	46
187	Ly Antigens Associated with T Cell Recognition and Effector Function. Immunological Reviews, 1984, 82, 47-78.	2.8	47
188	Qa ANTIGENS AND THEIR DIFFERENTIAL DISTRIBUTION ON LYMPHOID, MYELOID AND STEM CELLS. International Journal of Immunogenetics, 1984, 11, 265-281.	1.2	24
189	Comparison of thymic and peripheral T cell Ly-2/3 antigens. European Journal of Immunology, 1984, 14, 906-910.	1.6	37
190	Definition of new alloantigens encoded by genes in the Ly-6 complex. Immunogenetics, 1984, 20, 57-69.	1.2	36
191	Location of Ly-7 on mouse chromosome 12. Immunogenetics, 1984, 19, 539-543.	1.2	16
192	A new murine alloantigen: Ly-26.1. Immunogenetics, 1984, 19, 355-358.	1.2	3
193	The Ly-25.1 specificity: Definition with a monoclonal antibody. Immunogenetics, 1984, 19, 83-86.	1.2	10
194	Monoclonal antibody to murine neutrophils: identification of the Gm-2.2 specificity. Journal of Immunology, 1984, 133, 2619-23.	0.4	16
195	The H-2 dm1 mutation and Qa antigens. Immunogenetics, 1983, 18, 617-624.	1.2	9
196	Two "Qa" specificities: Qa-m7 and Qa-m8 defined by monoclonal antibodies. Journal of Immunology, 1983, 131, 546-7.	0.4	22
197	Description of a new Qa antigenic specificity, "Qa-m9," whose expression is under complex genetic control. Journal of Immunology, 1983, 131, 1363-7.	0.4	20
198	Differential expression of Qa-m2 alloantigen on murine hemopoietic progenitor cells. Selective enrichment for megakaryocyte progenitors. Experimental Hematology, 1983, 11, 527-41.	0.2	8

#	Article	IF	CITATIONS
199	In vivo and in vitro effects of monoclonal antibody to Ly antigens on immunity to infection. Cellular Immunology, 1982, 71, 127-138.	1.4	93
200	Description of a Qa-2 like alloantigen (Qa-m2). European Journal of Immunology, 1982, 12, 374-379.	1.6	28
201	Monoclonal antibodies to the murine Ly-2.1 cell surface antigen. Immunology, 1982, 46, 135-44.	2.0	59
202	Ly-15. Transplantation, 1981, 31, 339-342.	0.5	7
203	EFFECT OF A MONOCLONAL ANTI-LYT-1.1 ON THE FUNCTIONAL ACTIVITY OF PRECURSOR, EFFECTOR, AND REGULATORY CELLS SPECIFIC FOR MURINE ALLOANTIGENS. Transplantation, 1981, 31, 56-60.	0.5	5
204	The immunosuppressive effect of monoclonal anti-Lyt-1.1 antibodiesin vivo. European Journal of Immunology, 1981, 11, 1005-1012.	1.6	20
205	Cells mediating graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection Journal of Experimental Medicine, 1981, 153, 1044-1057.	4.2	204
206	Ly-15: a new murine lymphocyte alloantigenic locus. Transplantation, 1981, 31, 339-42.	0.5	5
207	A monoclonal antibody detecting the Ly-9.2 (Lgp 100) cell-membrane alloantigen. Immunogenetics, 1980, 11-11, 65-74.	1.2	30
208	Demonstration of carbohydrate- and protein-determined la antigens by monoclonal antibodies. Immunogenetics, 1980, 11-11, 467-482.	1.2	38
209	Flow microfluorometric analysis of alloantigen expression during T cell development. European Journal of Immunology, 1980, 10, 899-903.	1.6	8
210	Monoclonal antibodies to murine cell surface antigens. I. Lyt-1.1. Journal of Immunology, 1980, 125, 1618-24.	0.4	45
211	First Report of a Phase 1 Randomised Trial of Molecular Clamp-Stabilised Spike Protein-Based and MF59-Adjuvanted Vaccine for SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	2